This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): dimethylfumarate and monoethylfumarate salts, first-generation fumarate derivative, LASW1835, LASW-1835
Fumaderm is a oral, first-generation immunomodulator that contains fumaric acid esters.
The mechanism of action of dimethyl fumarate (DMF) is: (i) DMF interferes with intracellular thiols resulting in increased levels of reduced glutathione after prolonged exposure, through an unknown mechanism; (ii) increased glutathione levels inhibit redox-sensitive kinases, resulting in (iii) an inhibition of the phosphorylation and ubiquitination of I-kappa B, leading to (iv) an inhibition of NF-kappa B translocation. This pathway leads to the modulation of the NF-kappa B-dependent cascades of inflammatory cytokine production and adhesion molecule expression.
Fumaderm is produced by Fumapharm, which Biogen Idec acquired in June 2006. In December 2006, Biogen Idec acquired the right to distribute Fumaderm in Germany from Fumedica effective May 1, 2007. Fumedica continued to distribute the product until that time. Effective May 1, 2007, Biogen Idec began to promote Fumaderm in Germany through Almirall, a third party service provider.
In May 2012, Royalty Pharma announced that it had acquired an interest in the earn-out payable to the former shareholders of Fumapharm for $761 million in cash. The Fumapharm earn-out primarily represents an indirect interest in Biogen Idec's BG-12 for the treatment of relapsing-remitting multiple sclerosis (RRMS). The earn-out also includes an interest in Fumaderm for the treatment of moderate to severe plaque psoriasis.
Partners: Almirall Prodesfarma, S.A. Royalty Pharma AG
Additional information available to subscribers only: